Results 61 to 70 of about 14,491 (226)

The Impact of Genomic Profiling for Novel Cancer Therapy–Recent Progress in Non-Small Cell Lung Cancer [PDF]

, 2016
There is high expectation for significant improvements in cancer patient care after completion of the human genome project in 2003. Through pains-taking analyses of genomic profiles in cancer patients, a number of targetable gene alterations have been ...
Xie, Jingwu, Zhang, Xiaoli
core   +2 more sources

Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial [PDF]

, 2021
Background: Alectinib is a potent anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI) which is currently used in the first-line setting of advanced ALK+ non-small cell lung cancer (NSCLC). Despite favorable results in the metastatic setting,
Boni L., Gnetti L., Leonetti A., Minari R., Musini L., Tiseo M., Tognetto M., Ventura L., Verze M.   +8 more
core   +1 more source

Mycosis Fungoides Is a Proliferation of Multiple Mutational Subclones

The Journal of Dermatology, EarlyView.
ABSTRACT Mycosis fungoides (MF) is a unique type of lymphoma with an excellent prognosis presenting with a wide variety of clinical and histological findings. Recent sophisticated research techniques have revealed that very slow changes in the clinical and histological pictures of one patient over time are due to intratumoral heterogeneity.
Ryoma Honda, Toshihisa Hamada, Makoto Sugaya   +2 more
wiley   +1 more source

Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis

Frontiers in Oncology, 2021
ObjectiveTo systematically evaluate the efficacy and safety of alectinib versus crizotinib in the treatment of anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer.MethodsStudies about the efficacy of alectinib versus crizotinib in the ...
Hao Tang, Longyu Jin, Zhang Zhang, Zhibin Jiang, Zeeshan Malik   +4 more
doaj   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib

Cell Death and Disease
There is limited understanding of the phenomenon of reversible drug resistance, which is characterized by tumor cells regaining sensitivity when the drug is changed or withdrawn after a period of drug resistance. This phenomenon is usually not associated
Yihua Huang, Jie Huang, J. Zhan, Maojian Chen, Jiani Zheng, Junyi He, W. Fang, Li Zhang, Jing Li   +8 more
semanticscholar   +1 more source

IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report updated efficacy and safety results from the disease‐free survival (DFS) final and overall ...
Morihito Okada, Shunichi Sugawara, Yasutaka Watanabe, Haruhiro Saito, Toyofumi F. Chen‐Yoshikawa, Yasushi Goto, Wataru Nishio, Shizuka Nakagawa, Morihiko Hayashi, Hirotsugu Kenmotsu   +9 more
wiley   +1 more source

Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin

BMC Cancer, 2021
Background Photodynamic therapy with a photosensitizer such as protoporphyrin-IX, a light sensitive metabolite of heme synthesis, is a highly selective treatment for various carcinomas.
Bernhard Gillissen, Antje Richter, Frank Essmann, Wolfgang Kemmner   +3 more
doaj   +1 more source

Side effects of tyrosine kinase inhibitors in cancer treatment [PDF]

, 2018
Zaviralci tirozin-kinaz so multitarčna zdravila, ki prek zaviranja različnih celičnih procesov učinkujejo pri več vrstah rakavih boleznih. Čeprav so stranski učinki ob zaviralcih tirozinskih kinaz v splošnem prenosljivi, pa so lahko tudi resni in ...
Mencinger, Marina
core   +2 more sources

High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial. [PDF]

, 2023
This paper presents results from Cohort B (rearranged during transfection [RET], fusion-positive) of the Blood First Assay Screening Trial in patients with advanced non-small cell lung cancer (NSCLC) screened for genetic alterations using blood-based ...
Aix, S.P., Alatorre-Alexander, J., Bhagawati-Prasad, V., Dziadziuszko, R., Gadgeel, S.M., Maclennan, M., Mathisen, M.S., Mok, T., Peled, N., Peters, S., Ruf, T., Schleifman, E., Shagan, S.M., Vicuna, B.D.   +13 more
core   +1 more source